NO20043085L - Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet - Google Patents

Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet

Info

Publication number
NO20043085L
NO20043085L NO20043085A NO20043085A NO20043085L NO 20043085 L NO20043085 L NO 20043085L NO 20043085 A NO20043085 A NO 20043085A NO 20043085 A NO20043085 A NO 20043085A NO 20043085 L NO20043085 L NO 20043085L
Authority
NO
Norway
Prior art keywords
compositions
treatment
methods
nervous system
central nervous
Prior art date
Application number
NO20043085A
Other languages
English (en)
Inventor
Merouane Bencherif
Mario B Marrero
Original Assignee
Med College Georgia Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med College Georgia Res Inst filed Critical Med College Georgia Res Inst
Publication of NO20043085L publication Critical patent/NO20043085L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
NO20043085A 2001-12-14 2004-07-13 Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet NO20043085L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34058201P 2001-12-14 2001-12-14
US36993402P 2002-04-04 2002-04-04
PCT/US2002/039952 WO2003051302A2 (en) 2001-12-14 2002-12-13 Methods and compositions for treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
NO20043085L true NO20043085L (no) 2004-07-13

Family

ID=26992172

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043085A NO20043085L (no) 2001-12-14 2004-07-13 Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet

Country Status (13)

Country Link
US (2) US7067261B2 (no)
EP (1) EP1463481A4 (no)
JP (1) JP2005538683A (no)
CN (1) CN100371714C (no)
AU (1) AU2002360598B2 (no)
BR (1) BR0214929A (no)
CA (1) CA2470567A1 (no)
HU (1) HUP0501017A3 (no)
IL (1) IL162153A0 (no)
NO (1) NO20043085L (no)
NZ (2) NZ554913A (no)
PL (1) PL374384A1 (no)
WO (1) WO2003051302A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
DE112005001269T5 (de) * 2005-04-26 2008-05-29 Versitech Ltd. Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
CA2866540A1 (en) * 2006-03-20 2007-09-27 Spinifex Pharmaceuticals Pty Ltd. Method of treatment or prophylaxis of inflammatory pain
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
JP5153114B2 (ja) 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
JP2010510175A (ja) * 2006-11-10 2010-04-02 ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド 甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー／オリゴマー
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008109517A1 (en) * 2007-03-02 2008-09-12 University Of South Florida Neurodegenerative disease treatment using jak/stat inhibition
US20110262407A1 (en) * 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
EP3154540A1 (en) * 2014-06-13 2017-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising an at2r agonist for treating pain
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2023091439A1 (en) * 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216357A3 (en) 1985-09-25 1988-08-31 Nippon Zeon Co., Ltd. Phosphoramidite compounds and process for production thereof
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5369028A (en) * 1990-04-03 1994-11-29 The Salk Institute Biotechnology/Industrial Associates, Inc. DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same
US6440681B1 (en) 1990-04-03 2002-08-27 Merck & Co., Inc. Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US5986100A (en) 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
CA2709735A1 (en) 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
CA2331154A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
MXPA01012202A (es) 1999-05-24 2002-06-21 Targacept Inc Composiciones farmaceuticas y metodos de uso.
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
WO2001082978A2 (en) 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US6440970B1 (en) * 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
JP2003534344A (ja) 2000-05-25 2003-11-18 ターガセプト，インコーポレイテッド ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists

Also Published As

Publication number Publication date
HUP0501017A2 (en) 2006-01-30
IL162153A0 (en) 2005-11-20
US7067261B2 (en) 2006-06-27
CN1605027A (zh) 2005-04-06
JP2005538683A (ja) 2005-12-22
WO2003051302A2 (en) 2003-06-26
US20030158211A1 (en) 2003-08-21
BR0214929A (pt) 2006-05-30
AU2002360598A1 (en) 2003-06-30
AU2002360598B2 (en) 2008-02-14
EP1463481A4 (en) 2008-06-25
HUP0501017A3 (en) 2010-06-28
WO2003051302A3 (en) 2003-09-04
US20060160835A1 (en) 2006-07-20
NZ554913A (en) 2009-01-31
CA2470567A1 (en) 2003-06-26
NZ533259A (en) 2007-10-26
CN100371714C (zh) 2008-02-27
PL374384A1 (en) 2005-10-17
EP1463481A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20034056D0 (no) Proliferative sykdommer
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
EP1644021A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
EP1478438A4 (en) TECHNIQUES AND COMPOSITIONS FOR THE TREATMENT OF ASTHMA AND RELATED DISORDERS
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
NO20032156L (no) Behandling av angstforstyrrelser
NO20010390D0 (no) Behandling av angstsykdommer
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application